Crossmark

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

Crossref DOI link: https://doi.org/10.1007/s11060-019-03201-3

Published Online: 2019-06-05

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jaeckle, Kurt A. http://orcid.org/0000-0002-7827-463X
Anderson, S. K.

Twohy, Erin L.

Dixon, Jesse G.

Giannini, Caterina

Jenkins, Robert

Egorin, Merrill J.

Sarkaria, Jann N.

Brown, Paul D.

Flynn, P. J.

Schwerkoske, John

Buckner, Jan C.

Galanis, Evanthia
License Information

Text and Data Mining valid from 2019-06-05

Version of Record valid from 2019-06-05
More Information

Article History

First Online: 5 June 2019

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below